Eagle Pharmaceuticals, Inc. (EGRX)
NASDAQ: EGRX · IEX Real-Time Price · USD
4.075
+0.125 (3.16%)
Jun 20, 2024, 3:28 PM EDT - Market open

Eagle Pharmaceuticals Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year
20222021202020192018 2017 - 2012
Cash & Equivalents
55.3297.66103.16109.7878.79
Upgrade
Cash & Cash Equivalents
55.3297.66103.16109.7878.79
Upgrade
Cash Growth
-43.35%-5.33%-6.03%39.32%-31.28%
Upgrade
Receivables
72.4441.1551.124866.49
Upgrade
Inventory
47.7921.918.086.578.3
Upgrade
Other Current Assets
13.211.893.7215.110.26
Upgrade
Total Current Assets
188.75172.61166.07179.45163.84
Upgrade
Property, Plant & Equipment
1.171.642.082.22.4
Upgrade
Goodwill and Intangibles
163.3650.4152.6655.3357.85
Upgrade
Other Long-Term Assets
52.8829.0832.3917.5814.52
Upgrade
Total Long-Term Assets
217.4181.1387.1375.1174.76
Upgrade
Total Assets
406.16253.73253.19254.55238.6
Upgrade
Accounts Payable
18.9916.436.275.469.92
Upgrade
Current Debt
6.2525.61856.25
Upgrade
Other Current Liabilities
85.8432.3423.8228.3623.52
Upgrade
Total Current Liabilities
111.0974.3838.0938.8239.69
Upgrade
Long-Term Debt
56.22025.1433.5638.16
Upgrade
Other Long-Term Liabilities
5.32.93.9630
Upgrade
Total Long-Term Liabilities
61.512.929.0936.5638.16
Upgrade
Total Liabilities
172.677.2867.1875.3877.84
Upgrade
Total Debt
62.4725.6133.1438.5644.41
Upgrade
Debt Growth
143.94%-22.72%-14.06%-13.17%-7.06%
Upgrade
Retained Earnings
111.575.8684.4972.558.19
Upgrade
Comprehensive Income
-1.11-0.09000
Upgrade
Shareholders' Equity
233.56176.45186.01179.17160.76
Upgrade
Net Cash / Debt
-7.1572.0570.0271.2234.39
Upgrade
Net Cash / Debt Growth
-2.90%-1.68%107.11%-48.58%
Upgrade
Net Cash Per Share
-0.555.525.085.042.25
Upgrade
Working Capital
77.6798.23127.98140.63124.16
Upgrade
Book Value Per Share
18.0613.5213.8013.0310.88
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).